Advertisement

Topics

Novartis Treatment Reduced Cardiovascular Risk By 25 Percent In Trial

06:00 EST 14 Nov 2017 | Pharmaceutical Processing

The phase III results and analysis suggest that in the future, physicians may be able to identify patients who can achieve the greatest cardiovascular benefit from long-term canakinumab treatment.
Contributed Author: 
Novartis Pharmaceuticals Corp.

Original Article: Novartis Treatment Reduced Cardiovascular Risk By 25 Percent In Trial

NEXT ARTICLE

More From BioPortfolio on "Novartis Treatment Reduced Cardiovascular Risk By 25 Percent In Trial"

Advertisement
Quick Search
Advertisement
Advertisement